Table 1 Characteristics of 72 patients with gastroenteropancreatic neuroendocrine tumors
Item | Number (%) |
|---|---|
Age | |
Median | 51 |
Range | (27–82) |
Sex | |
Males | 38 (52.8) |
Females | 34 (47.2) |
Presenting symptoms | |
Incidental | 8 (11) |
Flushing/diarrhea | 7 (10) |
Primary tumor location | |
Pancreas | 21 (29.2) |
Other GIa tract | 51 (70.8) |
Ki-67 | |
≤ 2% | 35 (48.6) |
3–20% | 23 (31.9) |
> 20% | 8 (11.1) |
Not done | 6 (8.3) |
Pathology | |
Gastrinoma | 1 (1.4) |
Insulinoma | 1 (1.4) |
Paraganglioma | 1 (1.4) |
NET/NECb | 69 (95.8) |
WHO classification, 2017 | |
Well-differentiated, G1c | 41 (57) |
Well-differentiated, G2 | 21 (29) |
Well-differentiated, G3 | 4 (6) |
Neuroendocrine carcinoma | 5 (7) |
Unknown | 1 (1) |
Disease stage | |
Localized | 33 (45.8) |
Metastatic | 39 (54.2) |
Metastatic organ involvement | |
Lung | 11 (15.3) |
Liver | 31 (43.1) |
Peritoneum | 8 (11.1) |
Lymph nodes | 20 (27.8) |
Bone | 6 (8.3) |
Alkaline phosphatase | |
Normal | 48 (66.7) |
Elevated | 23 (31.9) |
Not done | 1 (1.4) |
Chromogranin A level | |
Normal | 11 (15.3) |
Elevated | 13 (18.1) |
Not done | 48 (66.7) |